Frazier Life Sciences Management, L.P. Phathom Pharmaceuticals, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.7 Billion
- Q2 2024
A detailed history of Frazier Life Sciences Management, L.P. transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 10,109,279 shares of PHAT stock, worth $176 Million. This represents 6.14% of its overall portfolio holdings.
Number of Shares
10,109,279
Previous 10,109,279
-0.0%
Holding current value
$176 Million
Previous $107 Million
3.01%
% of portfolio
6.14%
Previous 5.64%
Shares
3 transactions
Others Institutions Holding PHAT
# of Institutions
122Shares Held
59MCall Options Held
467KPut Options Held
34.9K-
Medicxi Ventures Management (Jersey) LTD7.46MShares$130 Million28.04% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$60.9 Million4.3% of portfolio
-
Invesco Ltd. Atlanta, GA3.14MShares$54.8 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.93MShares$51 Million0.0% of portfolio
-
Jennison Associates LLC2.76MShares$48 Million0.02% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $682M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...